Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Craig Seaman
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02098993CT.gov Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Chest Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Unfractionated Heparin (this asset) | Craig Seaman | P2 | CCC · 50 |
| Tocilizumab | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Tinzaparin | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Atorvastatin | Dr. med. Mahir Karakas | P3 | B |
| Aspirin | Dr. med. Mahir Karakas | P3 | B |
| Defibrotide | New York Medical College | P2 | B |
| a-001 | Anthera Pharmaceuticals | P2 | B |
| Budesonide | Vanderbilt University | P1 | CC |
| Azithromycin | University of Mississippi Medical Center | P1 | CC |
+2 more in the Acute Chest Syndrome cohort
Other indications for Unfractionated Heparin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Childhood Acute Lymphoblastic Leukemia | — | P4 | B · 59 |
| Venous Thromboembolism | — | P4 | B · 57 |
| Myocardial Infarction | — | P4 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Unfractionated Heparin in Acute Chest Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/unfractionated-heparin-acute-chest-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →